Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.
about
Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and ProgressionComparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE)Treatment of non-muscle invasive bladder cancer with Bacillus Calmette-Guerin (BCG): Biological markers and simulation studiesNew and contemporary markers of prognosis in nonmuscle invasive urothelial cancerDefining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancerBacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccineFemale with bladder cancer: what and why is there a difference?Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non-muscle-invasive bladder cancer patientsThe application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial.The 1973 WHO Classification is more suitable than the 2004 WHO Classification for predicting prognosis in non-muscle-invasive bladder cancerPrevious Bladder Cancer History in Patients with High-Risk, Non-muscle-invasive Bladder Cancer Correlates with Recurrence and Progression: Implications of Natural HistoryLymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor response of T1 tumors to bacillus Calmette-GuérinBladder cancer: a simple model becomes complex.Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now?CUA guidelines on the management of non-muscle invasive bladder cancer.Results of second transurethral resection for high-grade T1 bladder cancer.The Role of Population-Based Observational Research in Bladder CancerManagement of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapyThe management of BCG failure in non-muscle-invasive bladder cancer: an update.The value of EORTC risk tables in evaluating recurrent non-muscle-invasive bladder cancer in everyday practice.Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer.Developments in intravesical therapy for non-muscle-invasive bladder cancer.Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer.Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment.High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment.The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications.Immune therapies in non-muscle invasive bladder cancer.Gender differences in incidence and outcomes of urothelial and kidney cancer.Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study.Weight of the resected specimen after transurethral resection as a new predictive variable for recurrence of non-muscle-invasive bladder tumour.Tumor multiplicity is an independent prognostic factor of non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin immunotherapy.Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis.Prognostic value of inflammation or granuloma after intravesival BCG in non-muscle-invasive bladder cancer.Radical cystectomy for BCG failure: has the timing improved in recent years?The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study.Maximizing outcomes in genitourinary cancers across the treatment continuum.
P2860
Q26744754-A53F9D05-C7A9-44C9-A0FF-91CF5E79CF5AQ26744756-0314D0E3-6847-482C-A96F-E30A35FA5BF9Q26775541-58A7CB88-53E8-46A5-AB70-3BCC1CE69E11Q26798006-365F84B2-4B52-44B8-9C1D-25B65561D463Q26852084-9D18367A-91BD-4CE7-AAB1-E7CB06E88CA7Q27006765-D883C1B1-1E56-4CB2-AE22-3B1544AEB9E0Q28066115-F8E8E5AC-FFAC-4ABC-872A-E3DB73B8AC76Q33684090-60B9E185-1719-4845-B4BC-0B9198C10102Q33945057-5AE3BEE3-BFAB-43BD-A187-972639A1AD2CQ34452006-BD997578-2624-4D4F-8148-EB12E496C3BFQ35862328-3055E2BD-7CEA-4CB4-9A61-01D3D9041BB5Q35898208-477143C4-D886-4291-B876-7C0A69040AA0Q36108115-1DC794A4-A080-4CB2-9562-C91350D416FCQ36167778-4F5F6C48-5879-462B-B559-487F98B331E2Q36326208-58E67FA8-EC1F-4A2B-B1D9-48683A949923Q36481219-1AAB2BB7-F891-475B-B234-879351560358Q37053750-1F95C13C-78C2-413F-93C3-2302828654E2Q37053829-E5747468-7DFD-44D7-8460-779C4F70918DQ37235573-431349D1-D0D6-4446-937E-9263459B9292Q37472576-4E4F4D33-7ABE-4B20-8881-657BB6968C3AQ37711567-25D768BC-B994-48C0-82F6-59C33F604538Q37811051-E53A2282-71E0-455F-A174-51ADDC0FEED3Q37812604-4E2DB886-809D-4383-BE15-6927DF7E5602Q37813081-8603E407-BADC-4B65-924F-9098D562BE7AQ37833152-543AA13B-E89A-4598-8B5B-A12F2993549FQ38052445-4FEA0FAF-0D26-4E40-8ADA-61A5E9881D4BQ38156070-F3B017DF-2EF5-47DB-A3FE-17FACAEDEEE1Q38272240-3E82B2BA-AEF0-4E27-BB6A-AFDA09AFC90FQ38372571-7B09DFE2-BC5A-489B-AE45-A7272317D77FQ38599201-B2BA49EE-5182-4D98-B1D4-6B80A3727700Q39457058-2481235E-4E69-4181-A557-AB700D067A17Q41725909-F21A12E0-462A-43C5-805B-31C35CF170ACQ43705778-DA80ACF5-8677-4181-A2A3-3C6552E1CE15Q44356886-77A2719F-CEDF-48E5-B3EA-6726962EA6D7Q44529718-7BA8B23F-2358-4FB5-9B88-0C00CBB382CFQ44544915-FF96C9CE-6E26-4A48-96B4-1B58AB225D54Q46216660-4D94E668-92CA-42CF-9674-B18A837389EFQ46403824-8C5F13C7-E2F4-4053-889A-BAC121AD7E45Q46853658-55921CDB-4C0C-46E6-A276-8E92A0854C82Q50246373-A502B4CE-10AB-44C5-A2A7-D83B6A0F114D
P2860
Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Prognostic factors in patients ...... four randomized CUETO trials.
@ast
Prognostic factors in patients ...... four randomized CUETO trials.
@en
type
label
Prognostic factors in patients ...... four randomized CUETO trials.
@ast
Prognostic factors in patients ...... four randomized CUETO trials.
@en
prefLabel
Prognostic factors in patients ...... four randomized CUETO trials.
@ast
Prognostic factors in patients ...... four randomized CUETO trials.
@en
P2093
P1433
P1476
Prognostic factors in patients ...... m four randomized CUETO trials
@en
P2093
Anabel Gimeno
Ander Astobieta
Antonio Ojea
Carlos Pertusa
Club Urológico Español de Tratamiento Oncológico (CUETO)
Eduardo Solsona
Jesus Rodriguez-Molina
Jose Antonio Martinez-Piñeiro
Jose Emilio Camacho
Luis Martinez-Piñeiro
P304
P356
10.1016/J.EURURO.2007.10.006
P407
P577
2007-10-15T00:00:00Z